“…The MCS+ is being used with the advantage of easy operation and high reliability. Many studies have been made to assess different available apheresis machines regarding procedure time, platelet yield, product quality, adverse effects and other variables (Patel et al , ; Ranganathan, ; Altuntas et al , ; Tendulkar & Rajadhyaksha, ). For example, one study showed that MCS+ could produce almost the same amount of CD34+ compared with the Cosmic Backgoround Explorer (COBE) method, whereas the latter showed more potential (Rock & Sutton, ).…”